Dimopoulos, M. A., Leleu, X., Moreau, P., Richardson, P. G., Liberati, A. M., Harrison, S. J., . . . Yong, K. (2021). Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis.
Citación estilo ChicagoDimopoulos, Meletios A., et al. Isatuximab Plus Pomalidomide and Dexamethasone in Relapsed/refractory Multiple Myeloma Patients With Renal Impairment: ICARIA-MM Subgroup Analysis. 2021.
Cita MLADimopoulos, Meletios A., et al. Isatuximab Plus Pomalidomide and Dexamethasone in Relapsed/refractory Multiple Myeloma Patients With Renal Impairment: ICARIA-MM Subgroup Analysis. 2021.
Precaución: Estas citas no son 100% exactas.